Drug intelligence / Profile preview

CP205

Development stage: Unknown
Lead developer: Consegna Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

CP205 is a long-acting injectable (LAI) biologic formulation of butyrylcholinesterase (BChE) being developed by Consegna Pharma as a medical countermeasure for nerve agent exposure. The drug is designed to provide sustained protection, potentially up to 21 days, against organophosphate poisoning. It functions as a bioscavenger, utilizing the BChE enzyme to sequester and neutralize nerve agents in the systemic circulation before they can reach and irreversibly inhibit acetylcholinesterase at the neuromuscular junction and in the central nervous system. The program leverages Consegna's proprietary computational technology to optimize the delivery and pharmacokinetics of the recombinant enzyme.

Other names: butyrylcholinesteraseBChE

Targets

Butyrylcholinesterase

Beyond the preview

Go deeper on CP205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP205.

Explore the full profile